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ECM remodeling contributes to all stages of athero-
sclerosis. Proteolysis of ECM molecules probably par-
ticipates in the initial mononuclear leukocyte translo-
cation from the vascular lumen through the basement
membrane into subendothelium, traversal of medial
smooth muscle cells (SMCs) through the elastic lami-
nae into the intima, compensatory arterial enlargement,
plaque angiogenesis, and plaque disruption (1–3).
Previous studies have suggested involvement of both
serine proteases and MMPs in arterial diseases. Defi-
ciency of plasminogen reduced the development of
lesions in transplanted mouse arteries (4) and in arter-
ies of electrically injured mice (5). Hyperlipidemic mice
deficient in urokinase showed reduced aortic ectasia
(6), an effect attributed to reduced plasmin-dependent
activation of pro-MMPs (6).
Human atheromata overexpress the interstitial colla-
genases MMP-1 (7), MMP-13 (8), and MMP-8 (9) at sites
of interstitial collagen cleavage. MMPs 2, 3, 7, 9, 12, 14,
and others also localize in human atherosclerotic
plaques (7, 10–14). Overexpression of the MMP inhibitor
TIMP-1 reduced formation of aneurysms (15) and ath-
erosclerotic lesions (16) in animals, affirming a role for
MMPs in arterial remodeling and atherogenesis.
Beyond serine proteases and MMPs, we recently pro-
posed the participation of cathepsin S (Cat S) and Cat K
in atherogenesis. These cysteine proteases have potent
elastolytic (17, 18) and collagenolytic activities (19). Dis-
eased human arteries overexpress these enzymes and
exhibit a reciprocal deficiency of cystatin C, the most
abundant endogenous inhibitor of cysteine proteases
(1, 2). Biochemical studies suggest that Cat S and Cat K
account for most of the elastolytic activity extracted
from human carotid plaques. Multiple cell types found
in human atheroma can express Cat S. We have previ-
ously demonstrated that intimal macrophages as well
as SMCs in the tunica media express Cat S in human
atherosclerotic arteries (1). We also demonstrated colo-
calization of Cat S with lumenal and microvascular
endothelial cells (ECs) in human atheroma and with
microvascular ECs in wounded mouse skin (G.-P. Shi et
al., unpublished data). In vitro experiments showed
secretion of active Cat S by these atheroma-associated
cell types following exposure to inflammatory cytokines
found in atheroma. Our findings implicate Cat S in
atherogenesis along with serine proteases and MMPs.
Furthermore, Cat S, an essential protease acquired for
invariant chain processing, plays an important role in
antigen presentation. Cat S deficiency leads to impaired
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Human atherosclerotic lesions overexpress the lysosomal cysteine protease cathepsin S (Cat S), one of
the most potent mammalian elastases known. In contrast, atheromata have low levels of the endoge-
nous Cat S inhibitor cystatin C compared with normal arteries, suggesting involvement of this pro-
tease in atherogenesis. The present study tested this hypothesis directly by crossing Cat S–deficient
(CatS–/–) mice with LDL receptor–deficient (LDLR–/–) mice that develop atherosclerosis on a high-cho-
lesterol diet. Compared with LDLR–/– mice, double-knockout mice (CatS–/–LDLR–/–) developed signif-
icantly less atherosclerosis, as indicated by plaque size (plaque area and intimal thickening) and stage
of development. These mice also had markedly reduced content of intimal macrophages, lipids,
smooth muscle cells, collagen, CD4+ T lymphocytes, and levels of IFN-γ. CatS–/–LDLR–/– monocytes
showed impaired subendothelial basement membrane transmigration, and aortas from CatS–/–LDLR–/–
mice had preserved elastic laminae. These findings establish a pivotal role for Cat S in atherogenesis.
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chemoattractant protein-1 (MCP-1).immune responses (20, 21), which might also affect
atherogenesis (22, 23). Despite this plethora of observa-
tional and biochemical data, no direct evidence establish-
es a role of Cat S in atherogenesis. This study used Cat S–
deficient (CatS–/–) mice crossbred with atherosclerosis-
prone (LDLR–/–) mice to address this question directly.
Methods
CatS–/–LDLR–/– mouse generation and animal protocol.
CatS–/– mice were backcrossed more than ten genera-
tions onto the C57/BL6 background. These mice were
crossbred with LDLR–/– mice (also on the C57/BL6
background; The Jackson Laboratory, Bar Harbor,
Maine, USA). The resulting double knockout mouse
genotypes were confirmed using mouse tail genomic
DNA–derived PCR as described (20, 24). This study
used both CatS–/–LDLR–/– and control LDLR–/– mice.
Mice consumed an atherogenic diet (D12108; Research
Diets Inc., New Brunswick, New Jersey, USA) contain-
ing 20.1% saturated fat, 1.37% cholesterol, and 0% sodi-
um cholate (25). After 8, 12, and 26 weeks (n = 12/
timepoint/group), mice were used as described below.
Oil red O staining for lipids. Deposition of lipids in en-
face preparations of abdominal aortas (fixed with 10%
formalin) was determined by oil red O staining. Subse-
quently, the aortas were opened longitudinally to the
iliac bifurcation and pinned out on the surface of black
wax with 0.2-mm steel pins. They were then stained
with oil red O solution for 2.5 hours at room tempera-
ture on a shaker and washed three to four times in 85%
propylene glycol solution.
Immunohistochemistry. Serial cryostat sections (6 µm)
of mouse aortic arches were fixed in acetone, air dried,
and stained by the avidin-biotin-peroxidase method.
After limiting endogenous peroxidase activity with
0.3% H2O2 and nonspecific binding of primary anti-
body with 5% species-appropriate normal serum (Vec-
tor Laboratories, Burlingame, California, USA), we
incubated sections with primary antibodies diluted in
PBS supplemented with 5% species-appropriate nor-
mal serum for 90 minutes at room temperature. Incu-
bation with secondary antibodies for 45 minutes was
followed by avidin-biotin complex (ABC; Vector Labo-
ratories) for 30 minutes. The reaction was visualized
with 3-amino-9-ethylcarbazole (ready-to-use AEC;
DAKO Corp., Carpinteria, California, USA) followed
by counterstaining with Gill’s hematoxylin solution
(Sigma-Aldrich, St. Louis, Missouri, USA). Antibodies
used were: rabbit anti–mouse Cat S (1:90; ref. 20), goat
anti-smooth muscle α-actin (1:75; Santa Cruz Bio-
technology Inc., Santa Cruz, California, USA), rat
anti–mouse macrophage (Mac-3, 1:1,000; Pharmingen,
San Diego, California, USA), and rat anti–mouse T cell
(CD4, 1:100; Pharmingen), goat anti–rat IFN-γ (1:75;
R&D Systems Inc., Minneapolis, Minnesota, USA),
hamster anti–mouse monocyte chemoattractant 
protein-1 (MCP-1) (1:50; Pharmingen), biotinylated
anti–mouse VCAM-1 (1:60), and biotinylated
anti–mouse ICAM-1 (1:50; Pharmingen).
Verhoeff–van Gieson staining for elastin. This procedure
used the Accustain Elastic Stain kit (Sigma-Aldrich)
according to the manufacturer’s recommendations.
Picrosirius red staining for type I and type III collagen.
Formalin-fixed frozen sections were incubated for 4
hours in a freshly prepared 0.1% solution of Sirius Red
F3BA (Polysciences Inc., Warrington, Pennsylvania,
USA) in saturated aqueous picric acid. After rinsing
twice in 0.01 N HCl and distilled water, sections were
briefly dehydrated and mounted in Permount (Vector
Laboratories). Sirius red staining was analyzed by
polarization microscopy.
Mouse aortic SMC isolation and elastase assay. Mouse aor-
tic SMCs were isolated as described with modifications
(26). Briefly, mouse aortas were removed and separated
from fat and adventitia followed by digestion with 1×
collagenase type II (Worthington Biochemical Corp.,
Lakewood, New Jersey, USA) at 37°C for 10–15 minutes.
The adventitia was completely stripped under micro-
scopic visualization, the aortas were opened, and ECs
were removed by abrasion. The aortas were then
chopped and digested in 4 ml of type I collagenase (1
mg/ml; Worthington Biochemical Corp.) and elastase
III (0.125 mg/ml; Sigma-Aldrich) for 40–90 minutes at
37°C. Digestion was stopped by addition of 10 ml of
DMEM containing 10% FCS. Cells were then plated on
a fibronectin-coated 60-mm culture dish. After the first
two passages, cells were cultured on gelatin-coated cul-
ture dishes. Cell identity was verified by immunostain-
ing for α-smooth muscle actin and calponin. To assay
SMC elastase activity, SMCs were passaged onto 24-well
plates (1 ×105/well). After the cells reached confluence,
300 µg of [3H]elastin was added to each well followed by
24–48 hours of incubation in the presence or absence of
IFN-γ (500 U/ml). Culture medium was collected by
centrifugation (14,000 g for 15 minutes) and soluble
radioactive elastin was quantified as described (1).
Statistical analysis. To measure plaque size as well as the
percent-positive area for staining, longitudinal sections
of the aortic arch were analyzed microscopically for all
mice. As described previously (27), a 3-mm segment of
the lesser curvature of the aortic arch was defined prox-
imally by a perpendicular axis dropped from the right
side of the innominate artery. The percentage of the total
area of the aortic arch stained for SMCs, macrophages,
collagen, and lipids was determined using computer-
assisted image analysis (Image-Pro Plus; Media Cyber-
netics, Silver Springers, Maryland, USA).
We estimated atherosclerosis as well as immunohis-
tochemical staining for MCP-1, VCAM-1, and ICAM-1
by semiquantitative grading using the following crite-
ria: 0, no staining; 1, weak staining; 2, moderate stain-
ing; 3, strong staining. Atherosclerotic lesions were
graded as: 0, no lesion; 1, few macrophages underlying
endothelium; 2, fatty streak–like lesion; and three
grades (3 through 5) of atheroma, with the lower grades
corresponding to less-developed lesions. Scoring was
performed independently by two blinded observers.
Data for CatS–/–LDLR–/– and control LDLR–/– groups
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nonparametric Mann-Whitney test. A value of P ≤0.05
was considered significant.
Lipoprotein measurement. Blood samples were collected
by retro-orbital venous plexus puncture. Serum total cho-
lesterol and triglyceride were assayed by enzymatic meth-
ods using Sigma Diagnostics kit nos. 401 and 343
(Sigma-Aldrich), respectively, adapted for microtiter plate
assay. HDL was separated from LDL and VLDL choles-
terol with kit no. 352-4, also adapted for microtiter plate
assay. HDL cholesterol levels were then measured using
kit no. 401. LDL cholesterol was calculated as follows:
serum LDL cholesterol concentration (mg/dl) = total
cholesterol – HDL cholesterol – (triglycerides/5).
Mouse monocyte isolation, transmigration measurement,
and invasion. Monocytes from CatS–/–LDLR–/– and
LDLR–/– mice were isolated by Percoll gradient cen-
trifugation. Briefly, mouse blood was collected into
heparin (1:200; Sigma-Aldrich) followed by 1:1 dilu-
tion with 1× PBS. Diluted blood was laid over a Per-
coll gradient (1.04 g/ml; Amersham Biosciences
Corp., Piscataway, New Jersey, USA) and centrifuged
for 30 minutes at 900 g. The interface layer of mono-
cytes/lymphocytes was collected and cultured on a
Petri dish for 2 hours. Unattached lymphocytes were
removed by washing with RPMI and monocytes were
further cultured in RPMI.
Rabbit aortic SMCs and ECs were cocultured as
described (28). Briefly, 1 ×106rabbit aortic SMCs were
cultivated with EGM-2 media (containing 2% rabbit
plasma) on the filter for more than 3 weeks. The mix-
ture of type I and type IV collagen was then laid on the
filter of a Chemotaxicell chamber (Kurabo Inc., Osaka,
Japan) and incubated at 37°C for 1 hour to complete
gel formation. Then 2 × 105 rabbit aortic EC’s were
seeded on top of the gel; these became confluent in a
week. Monocytes (1 × 106) isolated from peripheral
blood of CatS–/–LDLR–/– or LDLR–/– mice were applied
to the EC layer (day 0). After 7 days of culture, samples
were fixed with 10% formalin, embedded in paraffin,
and sectioned (10 µm) for immunohistochemical
study. Sections were incubated with primary antibod-
ies: F4/80 (anti–mouse monocyte, ref. 29) or
anti–macrophage scavenger receptor class A, type I
(anti-MSR) (30) followed by secondary antibody con-
jugated with HRP (Amersham Biosciences Corp.).
After visualization with 3,3′-diaminobenzidine (Dojin
Chemical Co., Kumamoto, Japan), nuclei were coun-
terstained with hematoxylin. The numbers of mono-
cytes/macrophages attached to ECs and those that
had transmigrated into the matrix layer were counted
by two blinded observers using confocal microscopy
(TCS SP; Leica Microsystems GmbH, Heidelberg, Ger-
many) as described previously (28). Results are pre-
sented as mean ± SEM. Statistical comparisons were
made using the two-tailed Student paired ttest; a value
of P ≤0.01 was considered significant. The experiment
was repeated four times.
For the mouse monocyte invasion/transmigration
assay, cells were incubated overnight at room tempera-
ture in PBS in Boyden transwell chambers coated with
type I collagen (110 µg/ml; Celtrix Pharmaceuticals
Inc., Santa Clara, California, USA) and type IV collagen
(30 µg/ml; BD Biosciences, Bedford, Massachusetts,
USA). Briefly, monocytes were resuspended in serum-
free media at 1 × 105/ml, and 0.5 ml of suspension was
added to each well. The lower chamber was supplied
with 0.8 ml of complete media with 0.5 µg of mouse
recombinant MCP-1 (Pharmingen). The invasion assay
was carried out at 37°C for 16 hours followed by crys-
tal violet staining. Six microscopic fields were random-
ly chosen to count transmigrated cells.
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Table 1
Plasma lipid contents in mice fed with chow or high cholesterol diet
Plasma total Plasma total Plasma total Plasma total
Genotype Diet n cholesterol triglyceride HDL LDL
(mg/dl) (mg/dl) (mg/dl) (mg/dl)
WT 10 169.7 ± 49.7 104.6 ± 32.7 57.4 ± 4.5 91.4 ± 40.1
CatS–/– 12 171.5 ± 50.0 110.3 ± 42.3 55.6 ± 5.6 93.9 ± 24.0
LDLR–/– Chow 6 291.1 ± 44.7 112.8 ± 26.8 46.3 ± 18.7 222.3 ± 52.4
CatS–/–/LDLR–/– 6 237.2 ± 28.2A 116.3 ± 28.0 49.6 ± 18.8 164.4 ± 23.4A
WT 8 200.1 ± 43.3 115.2 ± 28.7 52.4 ± 8.9 124.6 ± 33.3
CatS–/– 8 215.2 ± 31.3 120.1 ± 25.3 62.3 ± 15.9 129.0 ± 25.7
LDLR–/– High cholesterol 6 1,519.7 ± 124.0 207.2 ± 38.1 49.1 ± 27.9 1,429.1 ± 149.8
CatS–/–/LDLR–/– (8 weeks) 8 1,348.8 ± 236.9 162.8 ± 82.6 50.4 ± 22.7 1,265.8 ± 233.9
WT 8 221.6 ± 52.7 118.0 ± 23.7 55.5 ± 8.7 142.5 ± 30.0
CatS–/– 8 235.1 ± 30.5 112.7 ± 24.2 57.6 ± 28.3 155.0 ± 33.1
LDLR–/– High cholesterol 12 1,355.2 ± 340.1 190.9 ± 39.7 64.2 ± 9.3 1,251.7 ± 343.4
CatS–/–/LDLR–/– (12 weeks) 12 1,214.4 ± 295.3 204.8 ± 60.3 70.2 ± 15.0 1,103.2 ± 396.2
WT 7 195.6 ± 35.7 121.5 ± 28.8 58.7 ± 13.2 112.5 ± 32.4
CatS–/– 7 180.5 ± 43.2 119.1 ± 31.5 62.0 ± 22.7 94.7 ± 24.2
LDLR–/– High cholesterol 11 851.7 ± 162.1 NA 54.1 ± 5.0 770.4 ± 198.8
CatS–/–/LDLR–/– (26 weeks) 11 949.1 ± 210.9 NA 57.8 ± 8.6 862.8 ± 170.5
AP < 0.04, CatS–/–/LDLR–/– mice fed with chow diet vs. LDLR–/– mice fed with chow diet. NA, not assayed.Results
Generation of CatS–/–LDLR–/– mice. LDLR–/– mice devel-
op atherosclerotic plaques when consuming a high-
cholesterol diet and provide a well-established model
of atherosclerosis (31).
To study the role of Cat S in atherogenesis, we gener-
ated double-knockout (CatS–/–LDLR–/–) mice by crossing
CatS–/– mice with LDLR–/– mice, both on the C57/BL6
background. PCR analysis of tail genomic DNA con-
firmed the presence of mutant alleles for both Cat S
(170 bp) (20) and LDLR (800 bp) (24), as well as the
absence of their corresponding wild-type alleles (data
not shown). Both CatS–/– and CatS–/–LDLR–/– mice were
apparently healthy and fertile, and exhibited mendelian
transmission of the mutant alleles. We noticed no obvi-
ous abnormality in vasculature, organ development,
gestation time, or food/water consumption.
Cat S deficiency does not affect serum lipids. In
agreement with earlier findings, LDLR
deficiency significantly increased plasma
total cholesterol and LDL levels but did
not change either HDL or triglyceride lev-
els (24). Disruption of CatS gene function
alone did not affect plasma total choles-
terol, triglyceride, HDL, or LDL levels in
mice consuming an atherogenic diet (Table
1).  CatS–/–LDLR–/– mice that consumed
either a chow or atherogenic diet showed
no significant differences in plasma total
cholesterol and total LDL levels compared
with similarly fed LDLR–/– mice (Table 1).
Cat S deficiency reduces atherosclerosis in
LDLR–/– mice. LDLR–/– mice fed an athero-
genic diet developed atherosclerotic lesions
with morphological characteristics similar
in many aspects to those seen in humans
(31). To evaluate the severity of atheroscle-
rosis in mice, we characterized lesions by (a)
lesion area in the abdominal aorta delin-
eated by lipid staining with oil red O (Fig-
ure 1), (b) quantitative morphometric measurement of
intimal thickening (area between internal elastic lami-
na and lumen) in longitudinal sections of aortic arches
(intimal area; Figure 2a), and (c) histological grading of
lesions in aortic arches (see details in Methods) (Figure
2b). Analysis of en-face preparations of abdominal aorta
stained with oil red O showed a statistically significant
reduction of plaque area in CatS–/–LDLR–/–mice after 12
weeks (60% reduction, P < 0.0001) and 26 weeks (30%
reduction, P <0.005) on an atherogenic diet (Figure 1).
Consistent with the observations on the abdominal
aorta, the aortic arches from CatS–/–LDLR–/– mice also
showed a statistically significant reduction in plaque
size (intimal area; Figure 2a) as well as stage of plaque
development (Figure 2b) compared with LDLR–/– mice
at all three timepoints tested. In comparison, Cat S sin-
gle-deficient mice consuming the high-cholesterol diet
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Figure 1
Cat S deficiency reduces the area of aortic lipid accumulation. After consuming the
atherogenic diet for 12 or 26 weeks, both CatS–/–LDLR–/– and LDLR–/– mouse
abdominal aortas were isolated and stained for lipid deposition with oil red O. The
left panels show representative specimens used to calculate the percentages of oil
red O–positive areas shown in the bar graphs on the right. No aortic lipid deposi-
tion was seen in mice fed an atherogenic diet for 8 weeks (data not shown).
Figure 2
Attenuated aortic arch atherosclerotic lesions in CatS–/–LDLR–/– mice. Aortic arches were sectioned and stained with anti–Mac-3 antibodies as
described in Methods. (a) Measurement of aortic arch intimal area. Neointimal area (mm2) was analyzed in 3-mm longitudinal sections of the
aortic arches. CatS–/–LDLR–/–mice showed statistically significant reductions in intimal areas at both the 12-week and 26-week timepoints com-
pared with LDLR–/– mice. (b) Illustration of atherosclerotic lesion grading. Each group of mice (n = 12) consumed an atherogenic diet. Lesions
were graded as displayed in the left panels. Cat S deficiency significantly reduced atherosclerotic lesions at 8, 12, and 26 weeks (right panel).(free of cholate) did not develop any lesions at any time-
point tested (data not shown).
Elastin preservation in CatS–/–LDLR–/– mice. The arte-
rial ECM contains abundant elastin. Degradation
(fragmentation) of elastic laminae contributes to
SMC penetration into the intima during the forma-
tion of atheroma, compensatory enlargement, and in
the extreme, development of atherosclerotic aneur-
ysms. Elastic laminae in the aortic arch showed pre-
served integrity in CatS–/–LDLR–/– mice compared
with those wild type for Cat S, a potent elastase (Fig-
ure 3a). The doubly-deficient mice showed signifi-
cantly fewer elastin breaks at both 12 weeks (P <0.001)
and 26 weeks (P  < 0.004) after initiation of the
atherogenic diet (Figure 3a). Importantly, as in
human atheromata (1), Cat S colocalizes with α-actin–
positive SMCs in the media underlying atheroscle-
rotic plaques in LDL–/– mice (Figure 3b). Further-
more, Verhoeff–van Gieson staining for elastin on
Cat S–stained sections revealed colocalization of 
Cat S–positive SMCs with breaks in the elastic lami-
nae (Figure 3b, right), supporting a role of Cat S in
elastolysis in situ. To examine whether Cat S from
SMCs can degrade extracellular elastin in vitro, we
isolated SMCs from both CatS–/– and control mice
and measured their elastolytic capacity. SMCs from
CatS–/– mice have much less elastase activity even
when stimulated with IFN-γ (P <0.0001) (Figure 3c).
Reduced SMC and interstitial collagen content of intimal
lesions in CatS–/–LDLR–/–mice. SMC migration from the
tunica media into the intima requires proteolytic
degradation of elastin. The early lesions in aortas of
CatS–/–LDLR–/– mice contained significantly fewer
SMCs than those in LDLR–/– mice, measured as the
percent of α-actin–positive area at 12 weeks (P < 0.05)
and 26 weeks (P < 0.003) (Figure 3, d and e). Picrosir-
ius red staining of the aortic arches revealed a signifi-
cant reduction in collagen content in CatS–/–LDLR–/–
mice compared with LDLR–/– control mice at the 12-
week timepoint (P <0.01) but not at the 26-week time-
point (Figure 3e). Atheromata in CatS–/–LDLR–/– mice
had significantly thinner fibrous caps at 26 weeks
(Figure 3, d and f, P < 0.001). The fibrous caps were
insufficiently developed at earlier timepoints to per-
mit accurate measurement. Reduction of both the col-
lagen content and the fibrous cap thickness may
reflect the decreased number of SMCs (the major
source of collagen in arteries) due to impaired SMC
migration across the internal elastic membrane that
separates the tunica media from the intima.
Cat S deficiency decreases macrophage and leukocyte accu-
mulation in aortic lesions. Macrophages sustain inflamma-
tion within atheromata and probably influence plaque
stability. Human atheromata that have ruptured and
caused fatal thrombosis typically have abundant
macrophages (32). The percentage of plaque area 
The Journal of Clinical Investigation | March 2003 | Volume 111 | Number 6 901
Figure 3
Preserved elastin in CatS–/–LDLR–/– mice. (a) Verhoeff–van
Gieson staining for elastin shows aortic arch elastic lam-
inae. The graph shows the number of discontinuities in
the elastic lamina enumerated in the 3-mm aortic arch
sections. Significant differences in elastin preservation
between CatS–/–LDLR–/– and LDLR–/– mice occurred at
both the 12-week and 26-week timepoints. (b) Cat S–
positive medial SMCs colocalized with sites of elastin
degradation in LDLR–/– mice. Serial sections of aortic
arches were stained for α-actin (top left) and Cat S (bot-
tom left). Verhoeff–van Gieson staining for elastin per-
formed after Cat S staining showed Cat S expression to
be colocalized with elastin fragmentation; arrows indicate
elastin breaks (right). (c) SMC elastase assay. IFN-γ–stim-
ulated SMCs from CatS–/– mouse aortas showed signifi-
cantly weaker elastase activity than was found in wild-type
cells (P < 0.0001). Three independent experiments yield-
ed similar observations. (d and e) Reduction of intimal
SMCs, collagen content, and fibrous cap thickness in
CatS–/–LDLR–/– mice. Longitudinal sections of aortic arch
were immunostained for α-actin (SMC content) and for
collagen content with picrosirius red. CatS–/–LDLR–/– mice
had significantly less SMC and collagen in intima than did
LDLR–/– mice. Percentages of positively stained areas were
calculated using computer-assisted image quantification
as described (27). Values represent mean ± SD, P values
≤ 0.05 were considered significant. (f) The thickness of
the fibrous cap of an aortic atheroma of each mouse was
measured using sections stained with oil red O as
described in Methods. Few if any fibrous caps formed at
earlier timepoints.composed of Mac-3–positive monocytes/macrophages
decreased significantly in CatS–/–LDLR–/– mice at both
the 12-week (P <0.007) and 26-week (P <0.0001) time-
points compared with LDLR–/–controls (Figure 4, a and
b, upper panels). Oil red O staining for lipid accumula-
tion in the aortic arch declined in parallel with the con-
tent of macrophages, the major repository of intracellu-
lar lipid in plaques, at both timepoints (P < 0.002 and 
P <0.001) (Figure 4b, bottom). Similar to macrophages
in human atheromata (1), Mac-3–positive macrophages
(Figure 4d, red) express Cat S (Figure 4d, blue) within
intimal lesions in LDLR–/–mice. These two antigens colo-
calize, as shown by double immunostaining on the same
section (Figure 4d, purple).
The leukocytic infiltrates in atheroma include lymphocytes
and mononuclear phagocytes. CD4+ T cells, the predomi-
nant lymphocytes found in human and murine ather-
osclerotic plaques, participate in the chronic immune
response characteristic of atherosclerosis (33, 34). We
therefore enumerated CD4+ T cells in aortic arches.
Lesions from CatS–/–LDLR–/– mice had significantly
fewer CD4+ T cells than did LDLR–/– controls (Figure
4c, top). These changes in lymphocyte accumulation
did not merely reflect the decreased lesion size in the
CatS–/–LDLR–/– mice, as their content was normalized
to lesion area. Consistent with the reduction of CD4+
T cells in the CatS–/–LDLR–/– mouse aorta, the amount
of the prototypic Th1 cytokine, IFN-γ, also diminished
significantly compared with its levels in LDLR–/– mice
(Figure 4c, bottom). Similar to macrophages, CD4+
T cells, though fewer in atheromata, also express
immunoreactive Cat S (data
not shown), suggesting that
Cat S might also influence T
lymphocyte trafficking during
atherogenesis.
Cat S deficiency impairs leuko-
cyte transmigration through suben-
dothelial basement membrane. We
first tested the possibility that
reduced leukocyte accumula-
tion in CatS–/–LDLR–/– mice
resulted from decreased expres-
sion of adhesion and chemoat-
tractant molecules. However,
we detected no difference in
the expression of VCAM-1,
ICAM-1, or MCP-1 at the early
timepoint (8 weeks) most
important for white blood cell
recruitment (Table 2) (35).
After 12 weeks and 26 weeks on
an atherogenic diet when
atheromatous lesions were
rather well developed, lesions
did show a statistically signifi-
cant decrease in immunoreac-
tive VCAM-1 (P <0.02 for both
the 12-week and 26-week time-
points) or MCP-1 (P <0.004 and P <0.006 for 12-week
and 26-week timepoints, respectively). In addition to
reduced local inflammatory activation, these changes
may reflect decreased atheroma formation (36).
ICAM-1 protein content did not differ among groups
at any time studied.
Alternatively, Cat S might participate in leukocyte
migration from peripheral blood by facilitating prote-
olytic degradation of subendothelial vascular basement
membrane. The nascent atheromata in LDLR–/– mice
(Figure 2, grade 1 and grade 2) had Cat S–positive
macrophages underlying the endothelium (Figure 5a).
We previously showed a similar pattern of Cat S expres-
sion in human fatty streaks (1). We tested this hypothe-
sis in vitro in a monocyte migration and differentiation
assay described previously (28). This assay measures
migration of peripheral blood monocytes isolated from
CatS–/–LDLR–/– and control LDLR–/– mice through a
monolayer of ECs cultured atop a mixture of type I and
type IV collagens, prominent components of the suben-
dothelial basement membrane (see details in Methods).
The formation of an EC monolayer as well as the deposi-
tion of a collagen I and collagen IV–containing basement
membrane has been previously demonstrated (28). After
7 days of incubation, 91% of the F4/80-positive mono-
cytes/macrophages (29) from CatS–/–LDLR–/– mice
remained in the upper chamber, and only 9% of these
cells transmigrated through the endothelial monolayer
and the subjacent collagen-containing substrate (Figure
5, d and f). In contrast, over 50% of LDLR–/– mono-
cytes/macrophages crossed into the SMC layer (Figure 5,
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Figure 4
Cat S deficiency changes the composition of atheromata. Longitudinal sections of the aortic
arch were immunostained for Mac-3 (macrophages) (a), oil red O (lipids), CD4 (T lympho-
cytes) or IFN-γ. (b and c) Computer-assisted image analysis quantified the percentage of posi-
tively stained areas (27). Values represent mean ± SD; P values ≤ 0.05 were considered signifi-
cant. (d) Double immunostaining for Cat S (blue, middle) and macrophages (Mac-3, red, left)
showed colocalization of these two antigens (purple, right). Analysis of four specimens showed
similar results. Mφ, macrophage. c and f, P< 0.004). Immunostaining for macrophage scav-
enger receptor-A confirmed the identity of these cells as
differentiated macrophages (Figure 5e, arrowheads).
These observations suggest involvement of Cat S in
peripheral blood leukocyte transmigration through the
vessel wall subendothelial basement membrane. This
process may contribute to superficial erosion of athero-
ma, a cause of some fatal coronary thrombi, particularly
in women and diabetics (37, 38).
To determine whether collagen-containing suben-
dothelial basement membrane proteolysis by Cat S
might contribute to blood-borne leukocyte transmi-
gration, a simple cell invasion assay was performed
using Boyden transwells coated with collagen types I
and IV, using MCP-1 as chemoattractant. Although
fewer CatS–/–cells (mean of six randomly chosen fields)
transmigrated through the collagen layer than did con-
trol cells (58 ± 22 vs. 92 ± 23), this trend
did not achieve significance (P > 0.05),
arguing against a major role for Cat S in
degrading collagen-containing basement
membranes. This finding agrees with the
weak collagenolytic activity of Cat S (39)
and suggests operation of other mecha-
nisms of inhibition of macrophage accu-
mulation, perhaps related to the reduced
levels of MCP-1 in atheromata of
CatS–/–LDLR–/– mice.
Discussion
Recent observations have implicated the
elastolytic cathepsins S and K in atheroscle-
rosis (1, 2). The present study sought direct
evidence for Cat S involvement in atheroge-
nesis using genetically modified mice.
These experiments showed in vivo that lack
of Cat S reduced atherogenesis in LDLR–/–
mice by more than 50% after 8 or 12 weeks
of consumption of an atherogenic diet, and
mice still showed significantly diminished
atheroma (∼30% reduction) at 26 weeks
(Figure 1 and Figure 2). This attenuation 
of atherosclerosis in CatS–/–LDLR–/– mice 
likely results primarily from the lack of Cat
S. We found no difference in other cysteine
proteases (Cat B and Cat L, examined by cys-
teine protease active site [125I]-JPM labeling)
nor in the expression of MMPs (MMP-2,
MMP-3, or MMP-9 examined by Western
blot analysis) in CatS–/–LDLR–/– compared
with  LDLR–/– macrophages (data not
shown). Nor did deficiency of Cat S affect
serum lipid levels or expression of other
cathepsins or MMPs by ECs (G.-P. Shi et al.,
unpublished data). The striking magnitude
and duration of this blunted lesion forma-
tion highlights the importance of under-
standing the mechanism(s) of Cat S involve-
ment in atherogenesis.
Although not conclusive, our results suggest several
possible mechanisms by which Cat S may contribute to
lesion formation. First, Cat S, one of the most potent
mammalian elastases (40), remains active at neutral pH
(18) and may participate in proteolysis of elastic laminae
in arteries (1, 2). We previously demonstrated in vitro
that SMCs activated by IFN-γ as well as differentiated
macrophages can express and secrete active Cat S and
degrade extracellular elastin. Either natural (cystatin C)
or synthetic inhibitors of Cat S can substantially block
this elastolysis (1, 2, 41, 42). Within the artery wall,
elastin fibers contribute to the vessel’s structural integri-
ty and regulate SMC migration and proliferation (43).
Mice with targeted disruption of the elastin gene die 2–3
days after birth due to malformed blood vessels (44).
Our present observations indicate that degradation or
remodeling of elastic laminae contributes to generation
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Table 2
Grading of adhesion molecule expression in atherosclerotic lesions
Western diet Mouse genotype MCP-1 VCAM-1 ICAM-1
8 weeks LDLR–/– 0.79 ± 0.88 1.37 ± 0.38 1.75 ± 0.69
CatS–/–LDLR–/– 1.00 ± 0.71 1.00 ± 0.77 1.33 ± 0.26
NS NS NS
12 weeks LDLR–/– 2.33 ± 0.61 2.75 ± 0.42 1.50 ± 0.71
CatS–/–LDLR–/– 0.29 ± 0.25 1.96 ± 0.56 1.17 ± 0.41
P < 0.004 P < 0.02 NS
26 weeks LDLR–/– 2.25 ± 0.69 3.13 ± 0.44 0.37 ± 0.34
CatS–/–LDLR–/– 0.50 ± 0.52 2.37 ± 0.38 0.83 ± 0.74
P < 0.006 P < 0.02 NS
NS, no significant difference.
Figure 5
Cat S deficiency impairs leukocyte transmigration. (a) Increased local expression of
Cat S by ECs and macrophages abutting the arterial basement membrane. Paraffin
sections of LDLR–/– mouse fatty streaks were stained with rabbit anti–mouse Cat S
antibodies (red color) and non-immune rabbit IgG (b). (c–e) In vitro monocyte
transmigration. Cat S deficiency inhibited transmigration of monocytes/macro-
phages through the EC monolayer and collagen-containing film prepared as
described in Methods. Transmigrated macrophages were detected by the mono-
cyte/macrophage marker F4/80 (arrows) (c and d) and macrophage scavenger
receptor (MSR) antibodies (arrowheads) (e). Asterisks and Fs indicate collagen
matrix and microporous filter, respectively. (f) The bar graph shows percentage of
monocytes/macrophages remaining on the EC layer (white bars) and the percent-
age that transmigrated into the collagen-containing gel (black bars). Six independ-
ent experiments showed similar results.and development of atheromatous lesions, indicating a crit-
ical role for elastin preservation in this postnatally acquired
disease as well. Indeed, in this study, Cat S had the greatest
overall effect on lesion development at 12 weeks, when
CatS–/–LDLR–/–mice still showed better preserved elastic lam-
inae in aortic arches (Figure 3a) and abdominal aortas (data
not shown) than in LDLR–/–mice. Similar to our earlier find-
ings in human atheromata (1), medial SMCs in LDLR–/–mice
also express abundant Cat S at the sites of elastic lamina
degradation (Figure 3b), suggesting a role for Cat S in this
process. Primary cultured CatS–/– SMCs stimulated with 
IFN-γ showed significantly lower elastolysis than did SMCs
from control mice (Figure 3c). Reduced elastin breakdown
may limit SMC entry into the intima across the elastin barri-
ers in CatS–/–LDLR–/– mice. The thinner fibrous cap and
reduced intimal collagen content may follow decreased SMC
accumulation in lesions, as these cells produce most of the
collagen in atherosclerotic lesions (45).
A second mechanism of Cat S function may involve
remodeling of the basal lamina or basement membrane of
the artery’s intimal layer. Immunostaining for Cat S showed
strong signals in the basement membrane regions of human
fatty streaks (1). We observed a similar pattern of Cat S
expression in fatty streaks of LDLR–/– mice (Figure 5a). To
enter the intima during early atherogenesis, leukocytes must
penetrate the arterial basement membrane, which contains
type IV and type I collagen, laminin, and fibronectin (46).
This study monitored monocyte transmigration in vitro
through layers of SMCs, collagen matrix, and ECs. Scanning
EM analysis demonstrated monocyte traversal through both
the EC monolayer and the underlying collagen matrix (28).
The present experiments suggest that Cat S may pave the
way for leukocyte entry by breaking down the subendothe-
lial basement membrane. Monocytes isolated from
CatS–/–LDLR–/– mice did not transmigrate the endothelial
monolayer overlying a layer of type I and type IV collagen
(Figure 5, d and f), suggesting a role for Cat S in blood-borne
leukocyte penetration through the arterial basement mem-
brane after endothelial adhesion. Although we currently
cannot define a clear mechanism for this process, Cat S may
play multiple roles including ECM degradation, monocyte
differentiation, and possibly even “reverse transmigration.”
Primary cultured monocytes from CatS–/– and control mice
did not show significantly different invasion/transmigra-
tion in a collagen-coated Boyden chamber, suggesting that
Cat S–mediated collagenolysis may not be the only factor
affecting monocyte basement membrane transmigration.
Monocyte immunostaining with F4/80, a marker for both
monocytes and macrophages, indicated that most of the
F4/80-positive cells from CatS–/–LDLR–/– mice are much
smaller in size (and are possibly monocytes) (Figure 5d) than
those (possibly macrophages) from control mice (Figure 5,
c and e). Therefore Cat S may also affect monocyte differen-
tiation in this context, although we lack direct evidence on
this point. During atherogenesis, monocytes also traverse
endothelium in the basal-to-apical direction (reverse trans-
migration) (47). Randolph et al. have shown that endoge-
nous signals can stimulate monocyte traversal across an
endothelial monolayer atop collagen matrix and that a 
significant fraction of these cells becomes dendritic cells
after reverse transmigration (48). Cat S may thus affect
monocyte reverse transmigration, although this issue
requires further investigation.
Our observations did not suggest a role for Cat S in
leukocyte recruitment as none of the adhesion or
chemoattractant molecules measured in lesions
showed differences between the two groups of mice
(Table 2, 8-week timepoint). Impaired leukocyte
transmigration at the early stage of lesion develop-
ment and/or reduced levels of cell adhesion molecule
(i.e., VCAM) and chemoattractant (i.e., MCP-1) in
lesions at later stages in CatS–/–LDLR–/– mice (Table 2)
may account for the reduced number of lesional
CD4+ T cells and macrophages and the reduced
amount of IFN-γ (Figure 4). In particular, MCP-1,
which was most affected by Cat S deficiency, plays a
critical role in monocyte-macrophage recruitment
and migration (49). However, the monocyte recruit-
ment/transmigration defect observed in CatS–/–
monocytes (Figure 5) may not be the major cause of
the retarded atherosclerosis observed in this study.
Indeed, MCP-1 levels declined strikingly at both the
12-week and 26-week timepoints (Table 2), in paral-
lel with diminished lesion macrophage content (Fig-
ure 4, a and b). Deeper understanding of the impor-
tance of MCP-1 participation in this setting may
require further experiments such as bone marrow
transplantation.
Cat S may also contribute to atherogenesis by
effects on formation and growth of neovessels.
Microvessels may influence plaque growth and
lesion stability (50). Administration of the angio-
genic factor VEGF was shown to significantly aug-
ment the experimental atheroma (51). In contrast,
atherosclerotic animals treated with inhibitors of
angiogenesis showed not only reduced intimal neo-
vascularization but also reduced plaque size (52).
Our recent observations suggested that Cat S may
contribute to the degradation of arterial ECM,
which provides a path for neovessel growth (53). Cat
S deficiency reduces microtubule formation in vitro
and microvessel growth in vivo (G.-P. Shi et al.,
unpublished data). Therefore, the impaired micro-
vessel growth observed in CatS–/– mice might limit
atherosclerotic plaque growth.
In addition, we and others have previously report-
ed that Cat S plays an important role in invariant
chain processing in antigen-presenting cells, which
leads to altered antibody class switching and pro-
duction (20, 21). Increased serum autoantibodies
against oxidized LDL correlate with atherosclerosis
in humans and animals (54, 55). Cat S deficiency may
cause impaired immune responses and T lymphocyte
activation and expansion. Indeed, the number of T
lymphocytes also decreased markedly in lesions of
CatS–/–LDLR–/– mice. Further, CD1 molecules medi-
ate presentation of lipid antigen to T cells and fur-
ther T cell activation by lipid-laden macrophages in
904 The Journal of Clinical Investigation | March 2003 | Volume 111 | Number 6human atheroma. CD1+ foamy macrophages congre-
gate with T cells in atherosclerotic plaques (56).
CatS–/– mice have defective CD1-restricted antigen
presentation (57), consistent with a role for this pro-
tease in antigen presentation by CD1+ macrophages.
Therefore, altered immune responses found in CatS–/–
mice may also contribute to the retarded atherogen-
esis in CatS–/–LDLR–/– mice.
In conclusion, this study provides direct in vivo evi-
dence for involvement of the cysteine protease Cat S in
atherogenesis in mice. The data presented support sev-
eral possible mechanisms that contribute to this
atherogenic role of Cat S. Our previous observations
in diseased human arterial tissue suggest a similar
function for this protease in human lesions. The pres-
ent findings firmly place this cysteine protease along-
side MMPs and serine proteases as proteolytic
enzymes involved in atherosclerosis. This work raises
numerous questions for future investigation and
underscores the need to consider Cat S as a therapeu-
tic target in arterial diseases.
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